3D brain organoid models of epilepsy patients with cortical dysplasia as personalised medicine platforms
Duration:
January 2021–January 2022
By combining patient specific stem cell-derived brain organoid models with detailed clinical data of epilepsy patients we aim to gain insight into the pathogenic processes underlying epilepsy and to develop and test personalised treatments. Taking advantage of the fact that brain organoids can capture brain development in vitro, here we propose to investigate to what extent brain organoids can recapitulate the brain pathology and seizure activity of cortical dysplasia epilepsy patients. This will reveal whether this model is a tractable platform for identifying effective anti-seizure medications for this often drug-resistant form of epilepsy.
